Company: LGNZZ
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000886163-25-000012
Chunk: 98

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-02-28
Form: 10-K
Item: Item 15
Chunk 98
---
33093August 9, 202310.110.11#*2022 Employment Inducement Plan10-Q001-33093August 9, 202210.210.12#Amendment to 2022 Employee Inducement Plan10-K001-33093February 29, 202410.1210.13#*Form of Stock Option Agreement under the Company’s 2022 Employment Inducement Plan10-Q001-33093August 9, 202210.310.14#*Form of Restricted Stock Unit Award Agreement under the Company’s 2022 Employment Inducement Plan10-Q001-33093August 9, 202210.410.15#*Form of Performance-Based Restricted Stock Unit Award Agreement under the Company’s 2022 Employment Inducement Plan10-Q001-33093August 9, 202210.510.16#*Separation Agreement, effective December 12, 2022, by and between Ligand Pharmaceuticals Incorporated and John Higgins10-K001-33093February 28, 202310.1410.17#**Severance Agreement, effective December 5, 2022, by and between Ligand Pharmaceuticals Incorporated and Todd C. Davis10-K001-33093February 28, 202310.1510.18#Severance Agreement and General Release dated as of August 2, 2024, between Ligand Pharmaceuticals Incorporated and Mr. Korenberg.10-Q001-33093November 8, 202410.210.19Tax Matters Agreement, dated as of November 1, 2022, by and among OmniAb, Inc.(f/k/a Avista Public Acquisition Corp. II) Ligand Pharmaceuticals Incorporated and OmniAb Operations, Inc. (f/k/a OmniAb, Inc.)8-K001-33093November 4, 202210.110.20*Amended and Restated Employee Matters Agreement, dated as of August 18, 2022, by and among Ligand Pharmaceuticals Incorporated, OmniAb Operations, Inc. (f/k/a OmniAb, Inc.), OmniAb, Inc. (f/k/a Avista Public Acquisition Corp. II) and Orwell Merger Sub Inc.10-Q001-33093November 8, 202210.110.21TR Beta Contingent Value Rights Agreement, dated January 27, 2010, among the Company, Metabasis Therapeutics, Inc., David F. Hale and Mellon